Shares of WuXi AppTec (WUXI APPTEC) plummeted by 5.36% on Monday, as the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).
In a statement, WuXi AppTec said it has not entered into any binding deals regarding the operations of WuXi ATU and acknowledged uncertainty as to whether it will eventually decide to dispose of the business or explore other options to retain and continue its operations.
The announcement has raised concerns among investors about the future prospects and potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。